Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe Partnership to Accelerate Drug Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by mstrmndon Nov 03, 2021 7:24pm

787 Views

Post# 34084601

RE:RE:RE:RE:RE:RE:Antibe Partnership to Accelerate Drug Pipeline

They are looking to get at least $1B for Otenaproxesul. This is the entry point for any player to take it. No point selling less, it's worth more.

fox7mf wrote: A buyout/takeover right now or soon would not, I believe, get us what most of us want for Antibe. How much could they possibly ask for the pipeline at the moment or in the next 6-12 months?

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia